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Abstract
Tau is a microtubule-associated protein, whose main function is the modulation of the 
stability of axonal microtubules. In physiological conditions tau is abundant in neurons 
while its expression in glial populations is low and restricted to astrocytes and oligo-
dendrocytes. The aggregation of tau in neurofibrillary or gliofibrillary tangles is the 
main hallmark of tauopathies, a complex group of human neurodegenerative conditions 
where tau hyper-phosphorylation causes its increased insolubility and aggregation lead-
ing to tangle formation and microtubule destabilization. Tau can be detected in biological 
fluids in physiological and pathological conditions. In several neurodegenerative demen-
tias, either associated or not to a primary tauopathy, tau levels are altered in a disease-
specific pattern, which can be used as a biomarker for disease diagnosis and prognosis. 
The study of tau levels in biological fluids has been mainly performed in the cerebro-
spinal fluid (CSF), although the recent development of ultrasensitive techniques allows 
the robust quantification of tau in blood-based biofluids such as serum and plasma. The 
presence of elevated total-tau in the CSF is assumed to reflect the degree of axonal dam-
age in the brain tissue. Consequently, highest total-tau CSF levels are found in sporadic 
Creutzfeldt-Jakob disease, which is characterized by massive neuronal damage and a 
rapid progressive course. Elevated total-tau is also detected in Alzheimer’s disease and 
dementia with Lewy bodies, while in other dementia conditions such as vascular demen-
tia, frontotemporal dementia and corticobasal degeneration are unchanged, inconclusive 
or not determined. Additionally, total-tau rises temporarily due to cerebral infarction. In 
contrast, elevated phospho-tau levels seem to be restricted to Alzheimer’s disease pathol-
ogy, most likely mirroring the presence of the hyper-phosphorylated form in the brain 
tissue, although phospho-tau levels are mainly unaffected in tauopathies. Additionally, 
isoforms and different structural and truncated tau forms have also been reported to be 
altered in neurodegenerative dementias. In this complex scenario the diagnostic accu-
racy of diverse tau forms as disease-specific biomarkers needs to be established. In this 
chapter, we summarize the current knowledge on the alterations of diverse tau forms 
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in biological fluids of neurodegenerative dementias and its relevance in the differential 
diagnostic context. Additionally, we explore how tau alterations in the brain tissue may 
explain the etiology of its regulated levels in CSF and blood.
Keywords: total tau, phospho-tau, neurodegenerative diseases, cerebrospinal fluid, 
serum, plasma
1. Introduction
Tau is a microtubule-associated protein produced through alternative splicing of the MAPT 
(microtubule-associated protein tau) gene. Tau is highly abundant in the axons of nerve cells [1] 
where it plays a role in the stabilization and dynamics of the microtubules. To a lesser extent tau 
is also localized in the synaptic compartments [2] where it is suggested to modulate postsynap-
tic receptor activity by interaction with a broad range of synaptic proteins [3]. Besides its neu-
ronal localization, tau is also expressed in oligodendrocytes, where it stabilizes microtubules 
during process outgrowth and myelination [4–6] and in astrocytes at trace levels [4], where it 
does not appear to be a major cytoskeletal protein. Although tau is mainly an intracellular pro-
tein, it can also be actively secreted by neurons to the brain interstitial fluid. The mechanisms of 
tau secretion under physiological conditions are not well understood, but it can be induced by 
neuronal hyperexcitability [7] and its release through ectosomal and exosomal vesicles [8, 9] or 
alternative secretory pathways [10] has been proposed. Additionally, under certain pathologi-
cal conditions associated to neuronal degeneration tau can be released from the neurons to the 
brain interstitial fluid, usually correlating with the degree of neuro-axonal damage.
Tau released into the interstitial fluid may drain into the cerebrospinal fluid (CSF) within the 
subarachnoid space as well as into blood. Therefore, alterations of tau levels in biological flu-
ids may mirror the pathological state of the brain in those conditions associated to neuronal 
degeneration. Additionally, since tau is hyper-phosphorylated in patients suffering from pri-
mary tauopathies and Alzheimer’s disease (AD), a tauopathy associated with beta-amyloid 
deposition, increased phospho-tau (p-tau) levels in biological fluids may reflect the undergo-
ing tau pathology in the brain tissue.
Consequently, the quantification of tau levels in biological fluids is extensively studied as a 
diagnostic and prognostic biomarker in a broad range of neurological conditions either asso-
ciated or not to a concomitant tauopathy. Additionally, the analysis of different tau forms is 
also explored in the evaluation of the efficacy of disease-modifying therapies and to better 
understand the underlying molecular mechanisms associated to neuronal degeneration and 
tau pathology.
2. Tau pathology and neuro-axonal damage
Tauopathies are a complex and heterogeneous group of neurodegenerative diseases charac-
terized by the presence of hyper-phosphorylated and aggregated tau forms in neuronal and 
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glial cells [11, 12]. The spectrum of tauopathies encloses more than 20 sporadic and famil-
ial diseases, in which their neuropathological phenotypes can be classified according to the 
involvement of different cell types (neurons of glial cells), affected brain regions, and the 
type of tau form/s associated to the pathological protein deposits [12]. In contrast to primary 
tauopathies where the common pathological hallmark is the presence of disease-related tau 
forms, AD is a neurodegenerative disease where tau pathology is accompanied by the accu-
mulation of abnormally folded amyloid beta peptides in the tissue in form of extracellular 
amyloid plaques [13].
Keeping this in mind, the understanding of correlation between different tau forms present 
in the biological fluids regarding and the pathological changes occurring in the brain tis-
sue is challenging. On one hand, there are neurodegenerative mechanisms not associated to 
tauopathies (or tauopathies associated to beta-amyloid deposition such as in AD), but leading 
to acute or chronic neuronal damage drive to a release of tau forms in their non-patholog-
ical (basal) state: i.e. basal phosphorylation levels and absence of truncated forms. On the 
other hand, in the presence of a tauopathy, tau release due to neuro-axonal damage could be 
accompanied by the release of its pathological forms (hyper-phosphorylated and truncated 
forms). In this regard, the tau biomarker field has been closely associated to the study of AD 
pathology since, among the group of tauopathies, AD cases are showing the most robust 
and clinically relevant alterations on tau levels in biological fluids. However, the precise cel-
lular and molecular mechanisms leading to tau alterations in biological fluids remain elusive. 
Indeed, the current knowledge about the pathophysiological mechanisms of these diseases 
does not completely explain the disease-specific changes observed in biological fluids.
3. Cerebrospinal fluid tau
Enzyme-linked immunosorbent assays (ELISA) has been used extensively for the analysis 
of tau concentrations in the CSF. The most established immunoassays are developed for the 
quantification of total-tau (t-tau), which detects non-phosphorylated and phosphorylated tau 
forms, and phospho-tau (p-tau), which detects tau being phosphorylated at specific epitopes. 
Among them, the quantification of phospho-threonine-181 (p-tau-181) is broadly extended for 
research and clinical diagnosis purposes, especially in the context of AD-related pathology. 
Additionally, several studies have also shown the usefulness of assays detecting phospho-
serine-199 (p-tau-199) and phospho-threonine-231 (p-tau-231) [14]. Finally, the recent devel-
opment of a non-phospho-tau assay detecting non-phosphorylated tau at positions Thr-175, 
Thr-181 or Thr-231 [15], extended the range of available tools for the dissection of the contri-
bution of each specific tau form in the pathology of the spectrum of neurological conditions 
with altered tau concentrations in the CSF.
3.1. Total tau
The presence of increased total-tau (t-tau) levels in the CSF is reported in several neurodegen-
erative diseases such as sporadic Creutzfeldt-Jakob disease (sCJD), AD and dementia with 
Lewy bodies (DLB) [16–18].
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The highest t-tau levels are recurrently detected in sCJD, the most common form of human 
prion disease where deposition of prion protein, gliosis and massive neuronal damage accom-
panied with spongiform degeneration are common neuropathological hallmarks in the brain 
tissue [19]. The first report on the presence of high t-tau in the CSF of sCJD cases was in 1997 in 
a relatively small cohort of cases [20]. Further, several studies validated these observations 
in large populations [21–24]. A cut-off point of 1300 pg/mL t-tau was established for the dis-
crimination of sCJD from non-CJD cases [21] and although t-tau is not included in the World 
Health Organization diagnostic criteria for sCJD, its quantification is used in several world-
wide diagnostic centers as a supportive tool in the differential diagnosis of prion diseases.
In sCJD, patient’s molecular subtype is composed of two different kinds of information: (1) 
codon 129 genotype in the PRNP gene (MM, MV, or VV) and (2) prion protein (PrP) type (1 or 2) 
and it is a prognostic marker for disease progression and patient survival [19]. The different 
progression rates for each molecular subtype are associated to their differential neuropatho-
logical hallmarks, which in turn reflect the degree of neuronal degeneration. Accordingly, a 
significant association between CSF t-tau levels and sCJD molecular subtype was reported [25, 
26]. Additionally, CSF t-tau levels are inversely associated with disease duration, suggesting 
a role for CSF t-tau as a prognostic marker for sCJD [27]. While t-tau protein tends to increase 
in sensitivity from onset to the advanced stage, these changes are only statistically significant 
in patients with methionine-valine (MV) heterozygosis at codon 129 in the PRNP gene [28].
Besides sporadic forms, prion disease can also present a genetic (or hereditary) etiology [29]. 
Hereditary prion diseases are a heterogeneous group of conditions classified as familial or 
genetic CJD prion diseases (gCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS-S) and 
fatal familial insomnia (FFI), all of them associated to mutations in the prion protein gene 
and with an autosomal inheritance pattern. The most common gCJD types in the European 
population are those associated to mutations at codon 200 (E200K) and codon 210 (V210I). 
From a clinical and neuropathological point of view gCJD E200K and gCJD V210I resemble 
sCJD [30, 31]. Indeed, gCJD cases are often misclassified as sCJD in the absence of family 
history and genetic testing. In agreement with this, CSF t-tau levels in gCJD patients show 
levels comparable to those in sCJD [22, 32]. Instead, in GSS-S (associated to several mutations 
such as P102L, P105L, A117V, F198S) and FFI (associated to D178N mutation accompanied 
by a cis-129 M), CSF t-tau is usually below the sCJD cut-off point, [22, 32]. These differences 
are explained by the differential clinico-pathological hallmarks observed in these cases. First, 
GSS-S and FFI patients usually present a slower disease progression and prolonged disease 
duration compared to sCJD and gCJD cases [30]. Secondly, the brain regions affected are not 
overlapping those affected in sCJD. Indeed, FFI cases present a pathology which is usually 
restricted to the thalamic and olivary nucleus with spongiform changes in the cerebral cortex 
only in patients with long disease duration [30, 33, 34]. In contrast, neuropathological findings 
in GSS-S cases are heterogeneous depending on mutation type, but in general a widespread 
accumulation of PrP positive plaques in the cerebral and cerebellar cortices and the basal 
ganglia is observed [35, 36]. Although t-tau quantification lacks of clinical significance in the 
differential diagnosis of FFI and GSS-S, it is worth to mention that their mean CSF t-tau levels 
are increased compared to controls [22] indicating that, at some extent, t-tau may also reflect 
brain damage occurring in both conditions.
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In AD, CSF t-tau is considered as one of the three core biomarkers together with p-tau and 
amyloid beta-42. The first studies reporting elevated t-tau concentrations in AD patients com-
pared to controls date from 1995 [37–40]. Since them these results have been replicated in 
many studies [41, 42] with a predictive value around 90%.
Since t-tau is considered a marker of neurodegeneration, its levels are proposed to be changed 
latter during the progression of the disease and correlating with clinical symptom severity. 
This is in contrast to amyloid beta peptides which become abnormal before alterations in 
neurodegenerative biomarkers and cognitive symptoms are detected [43]. Importantly, as 
CSF t-tau reflects the intensity of acute neuronal damage and chronic neuronal degeneration 
elevated t-tau levels in MCI patients has been demonstrated to predict the progression to 
dementia [44], especially in short-term prognosis [45]. These observations are in agreement 
with a meta-analysis study that strongly supports the use of CSF t-tau in the identification 
of MCI-diagnosed subjects at higher risk of evolving to AD [46]. However, higher predictive 
values are reached when combined with p-tau, amyloid beta-42 and/or imaging biomarkers 
[45, 47]. Indeed data from longitudinal studies indicate that the combination of CSF t-tau, 
p-tau and amyloid beta-42 at baseline reach high prognostic values (95% sensitivity and 83% 
specificity) in the detection of early AD cases with MCI [48].
Besides the well documented elevated t-tau levels in sCJD, AD and DLB, several studies 
found slightly elevated t-tau levels in the spectrum of frontotemporal dementia (FTD)-related 
disorders [17] as well as in vascular dementia (VaD) [49, 50], although the reproducibility 
of these alterations are under discussion [17, 51]. Although meta-analysis studies support 
the presence of elevated t-tau levels in frontotemporal lobar-degeneration (FTLD) and VaD, 
these alterations are not as high as those detected in AD and CJD [52]. Importantly, altera-
tions on t-tau levels in VaD and FTLD are dependent on the heterogenic presentation of these 
conditions. For instance, elevated t-tau is observed in VaD patients without progressive leu-
koaraiosis, while VaD patients with progressive leukoaraiosis have normal t-tau values [49]. 
Additionally, studies in VaD cases may have selection bias as co-occurrence of vascular and 
AD-related pathology is well-known [53]. In regard to FTLD cases, the two major subtypes, 
FTLD-TDP (FTLD with TAR DNA-binding protein 43 inclusions) and FTLD-tau (FTLD with 
tau inclusions) did not seem to differ on t-tau levels [54], although it has been recently shown 
that t-tau harbors a better discrimination rate than TDP-43 proteins in the differentiation of 
both FTLD subtypes [55]. Overall, in FTLD cases, despite the presence of slightly to moderate 
increased tau levels compared to controls in several studies, these differences, when observed, 
do not harbor clinical significance [56]. However, a potential prognostic role of t-tau levels in 
FTD has been suggested as non-inherited FTD patients with high t-tau levels (≥400 pg/mL), 
who had shorter survival than those with low levels. Instead, p-tau concentrations were not 
associated with disease prognosis [57].
In Parkinson’s disease dementia (PDD) t-tau levels are also elevated compared controls or to 
Parkinson’s disease patients with normal cognition, but lower than those detected in DLB [58, 
59]. Whether elevated levels of t-tau in PDD are related to an underlying tau pathology par-
ticipating in the development of dementia, similar to AD, or just reflecting increased neuro-
axonal damage compared to PD cases is still a matter of debate.
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In corticobasal degeneration (CBD), initial reports suggested the presence of elevated t-tau 
levels [60, 61], but decreased or non-altered levels were later reported in other studies [62, 63]. 
Similarly, patients with progressive supranuclear palsy (PSP) showed total-tau levels compa-
rable to those detected in controls [61, 63].
Increased CSF t-tau levels in normal pressure hydrocephalus (NPH) patients compared to 
controls have also been reported [64]. Interestingly, t-tau levels correlated with the severity of 
dementia, urinary incontinence, and gait disturbance. However, further studies have not been 
able to replicate the presence of elevated t-tau in NPH patients [65, 66].
In Huntington’s disease (HD), a recent study reported elevated levels of CSF t-tau in gene 
expansion carriers compared with their control subjects. Additionally, t-tau concentrations 
were associated with phenotypic variability, thus a role for t-tau as a biomarker of disease 
progression was proposed [67]. However, a diagnostic role for t-tau in HD is excluded as no 
differences between HD patients compared with pre-manifest gene expansion carriers have 
been reported [68].
As a marker of neuronal damage, elevated t-tau levels have been reported in acute stroke [69] 
and head trauma [70]. CSF t-tau levels in acute brain injury present a transitory peak. For 
instance in traumatic brain injury (TBI), t-tau levels increased shortly after contusion, peaking 
in the second week post-trauma, slowly decreasing after this period and reaching basal values 
at 43 days [70]. Instead, in Olympic boxers subjected to repetitive trauma t-tau levels increased 
after boxing and remained elevated after a rest period of at least 14 days [71]. In acute stroke, 
t-tau levels are associated to disease severity and long-term outcome [72]. The sizes and local-
ization of the lesion generally affects the profile of CSF t-tau levels after stroke which vary 
to a great extent, generally reaching maximum levels after 3 weeks to 1 month and return-
ing to normal levels after 3–5 months [69, 73]. Other neurological conditions with transiently 
elevated t-tau levels include acute Wernicke’s disease [74, 75], after chemotherapy treatment 
for hematologic malignancies [76], and patients with temporary neurologic dysfunction after 
aortic surgery [77]. Altogether, these studies support the idea of CSF t-tau reflects the degree 
of brain injury and harbors a prognostic value in transient acute neuronal damage syndromes.
An important confounding factor in the biomarker field is the age of subjects in the study. In 
this regard, the discriminative power of CSF t-tau is higher in young old (<70 years) than in old 
(≥70 years) control and AD cases, indicating that CSF t-tau loses its discriminative power along 
the aging process [78]. Therefore, the age effect should be considered when establishing the 
diagnostic parameters of t-tau quantification as CSF biomarker. Increased t-tau levels during 
aging in healthy individuals have been validated in several independent cohorts [79], which 
in turn were associated to ApoE genotype [80, 81]. Consequently, age-dependent t-tau cut-off 
values in neurologically and psychiatrically healthy individuals have been established [82].
3.2. P-tau
While t-tau reflects axonal degeneration, p-tau levels reflect the phosphorylation state of tau 
in the brain tissue. This idea is supported by the absence of alterations in p-tau in neurologi-
cal diseases presenting neuronal damage but no p-tau pathology in the brain tissue, such as 
in acute stroke [69].
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Contrary to t-tau, elevated CSF p-tau levels seem to be more restricted to AD cases [83]. This is 
an interesting recurrent observation as aberrant tau phosphorylation also occurs in the brain 
tissue of tauopathies such as FTD with Parkinsonism linked to chromosome 17 (FTDP-17), 
Pick disease (PiD), CBD and PSP leading to aggregation into neurofibrillary tangles (NFT) 
and axonal transport dysfunction [84–86].
Neurofibrillary changes are composed of hyper-phosphorylated tau forms that correlate with 
disease duration and severity [87]. Indeed, the severity of cognitive impairment correlates 
better with the burden of neocortical neurofibrillary tangles than with amyloid pathology 
[87–89]. While meta-analysis studies indicate that CSF p-tau levels are a moderate prognos-
tic marker in AD [90], longitudinal studies show that p-tau-181 levels correlated with the 
progression of cognitive decline [91]. Additionally, a low p-tau-181/tau ratio has also been 
reported as a strong predictor of cognitive decline [92]. In contrast, p-tau-231 levels correlate 
with the rate of hippocampal atrophy in AD cases, which are independent of disease dura-
tion and severity [93] as well as with a reduction hippocampal volume detected by magnetic 
resonance imaging (MRI) [94]. Since rates of hippocampal atrophy are suggested to reflect 
reduction of neuronal density, these observations suggest that p-tau231 is directly associated 
to extensive neuronal damage but not to disease stage. Additionally, p-tau-199 levels have 
been shown to be useful in the discrimination of AD patients from non-AD-related dementia 
and non-demented patients in a large-scale multicenter study [95].
A comparative study on p-tau231, p-tau181 and p-tau199 performance showed that the three 
p-tau forms were significantly elevated in patients with AD compared with FTD, DLB, VaD 
and control cases [96]. This study also indicated that p-tau231 and p-tau181 assays performed 
similarly in the discrimination of AD from non-demented controls, whereas the p-tau199 
assay showed a weaker discriminatory value. However, the combinations of the three mea-
surements did not add discriminative power compared to single measurements. Although 
alternative p-tau epitopes have been studied in the context of AD pathogenesis, it is gener-
ally considered that p-tau181, 199 and 231 are those more characteristic to AD. Indeed, most 
studies have focused on p-tau231 and p-tau181 [14], which in turn, are the most standardized 
assays for p-tau quantification.
For p-tau-181, a cut-off of >60 pg/mL is generally used to define pathological levels due to AD 
pathogenesis [97].
While other p-tau species have also been measured such as p-tau199, p-tau199 + 202, as well as 
p-tau396 + 404, importantly, p-tau levels in AD are increased not only compared to controls, 
but also compared to other tauopathies and neurodegenerative diseases [98]. Measurement 
of them becomes a useful marker in the differentiation of AD from its most relevant differen-
tial diagnoses. Phosphorylation at Thr-231 is helpful in the discrimination of AD from FTD, 
and its levels are correlated with disease progression, whereas p-tau-181 (the most estab-
lished p-tau assay [99]) improves the differentiation between AD and DLB [96, 100, 101]. 
Additionally, p-tau, when used in combination with amyloid beta-42 (p-tau/amyloid beta-42 
ratio), shows the best diagnostic performance in the discrimination of AD from FTLD [102]. 
This meta-analysis study also reports that p-tau alone would be more useful for high Mini-
Mental-State-Examination (MMSE scores), while p-tau/amyloid beta-42 would be preferable 
for low MMSE scores and younger patients.
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Several explanations have been postulated for the specific preserve of high CSF p-tau concen-
trations in AD. First, it could be that primary tauopathies may present different phosphory-
lation profiles than those observed in AD. While the complete differential phosphorylation 
signatures in the spectrum of tauopathies is still not completely defined, in AD, tau is hyper-
phosphorylated at multiple sites (>30 sites). However, presence of tau hyper-phosphorylation 
at several epitopes such as 181, 199, 231,396 and 404 is a common hallmark in tauopathies [103].
A decrease on CSF t-tau in non-AD tauopathies could compensate the absence of elevated 
p-tau levels. However, t-tau levels are altered neither in the brain, nor in the brain tissue of 
non-AD tauopathies. Another aspect to be considered is the differential susceptibilities to 
clearance between tau forms. While tau turnover is delayed for insoluble forms, it is acceler-
ated for soluble and phosphorylated tau [104]. Therefore, it is tempting to speculate that the 
combination of some or all these factors may have an influence in the differential CSF t-tau 
and p-tau profiles observed between tauopathies and AD.
CSF p-tau levels (p-tau-181) have also been reported to be moderately increased in CJD [17, 
105]. Although p-tau values in sCJD are only from marginal to slightly elevated, most likely 
reflecting basal phosphorylation of tau molecules released into the CSF as a consequence of 
neuronal damage, these alterations are subtype-dependent. In fact, sCJD subtypes VV2 and 
MV2K showed the highest p-tau levels positively correlating with the amount of tiny tau 
deposits in brain areas showing spongiform change [24]. In agreement with these observa-
tions higher p-tau levels were detected in PRNP codon 129 VV cases compared to MM and 
MV cases where prion type was unknown [27].
Compared to controls, slightly increased p-tau concentrations have been reported in DLB [17], 
an observation supported by meta-analysis studies [52]. However, a large amount of studies 
report normal p-tau concentrations [106–109]. While several studies detected similar concen-
trations between DLB, PD, and PDD groups [22, 110], other reports suggest that among the 
group of α-synuclein aggregation disorders, DLB patients show the highest levels of p-tau [59].
Although it is broadly accepted that p-tau levels in FTLD are lower than those reported in AD 
and similar to controls [111], it has been recently shown that CSF p-tau levels are positively 
correlated with postmortem tau pathology (cerebral tau burden) [112]. Another interesting 
finding of this study was the observation that CSF p-tau levels in FTLD-TDP were lower than 
those detected in FTLD-tau.
In contrast to t-tau, p-tau levels are not elevated in acute brain injury or in TBI [69, 71, 73]. 
These results support the idea that CSF t-tau and p-tau reflect different pathogenic processes 
occurring in the brain tissue. While t-tau would be associated to the degree of neuro-axonal 
damage, p-tau would mirror the presence of hyper-phosphorylated tau forms, and therefore, 
the presence of neurofibrillary tangles.
Interestingly, a straightforward association has been suggested between ischemic events, tau 
hyper-phosphorylation and the formation of NFT. In this regard, hyper-phosphorylated and 
truncated tau-forms, resembling those detected in AD, accumulate after a transient cerebral 
ischemia [113, 114]. In humans NFT pathology is detected in TBI, but presenting remarkable 
differences in terms of temporal and regional affection: in TBI, NFT are concentrated in the 
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superficial layers in the neocortex, whereas in AD they predominate in the deep layers [115, 
116]. Additionally, in mouse model of repeated TBI, elevated p-tau without NFT formation 
was observed in aged mice overexpressing human tau [117]. Finally, the absence of altered 
p-tau levels in the CSF of acute brain damage could also be explained by the presence of dif-
ferent isoforms of aggregated tau. Indeed, this might also explain the unaltered CSF p-tau 
levels in tauopathies showing NFL pathology such as PSP [118].
3.3. P-tau/t-tau - (t-tau/p-tau) ratio
As described above, the partial overlap on t-tau levels observed in sCJD and AD cases decreases 
the specificity of tau quantification in the differential diagnostic context of both diseases. An 
interesting addition to the biomarker field was the observation that p-tau/t-tau ratio greatly 
improved the discrimination of sCJD cases, not only from AD, but also from other tauopathies 
showing increased t-tau levels. This finding was initially reported by Riemenschneider and 
colleagues in a small cohort of sCJD cases (n = 20) [119] and further validated by many inde-
pendent studies in large sample populations [16, 120, 121]. Diagnostic parameters and cut-off 
values were calculated in a cohort of more than 1000 sCJD cases [22]. For the discrimination 
of sCJD from neurological controls and AD the area under the curves were from 0.996 and 
0.990 respectively, indicating that p-tau/t-tau ratio is able to almost fully discriminate sCJD 
from non-CJD cases.
Finally, p-tau/t-tau ratio has been proved in independent studies to discriminate the two 
main forms of FTLD; FTLD with TAR DNA-binding protein 43 (TDP-43) inclusions (FTLD-
TDP) and FTLD with tau inclusions (FTLD-tau), with reduced p-tau/t-tau ratio detected in 
cases with FTLD-TDP pathology [122, 123]. This goes in line with the recent observation that 
patients with primary progressive aphasia with a non-AD profile (presumably FTLD) were 
stratified in two clusters according to p-tau/t-tau ratio, possibly corresponding to FTDP-tau 
and FTDP-TDP pathologies [124].
3.4. Non-p-tau
Recently, an assay able to reliably measure CSF concentrations of non-phosphorylated tau 
(non-p-tau) has been developed. The assay specifically measures non-p-tau at epitopes 175, 
181 or 231 [15]. The non-p-tau CSF levels in AD cases (at MCI or dementia stages) were 
increased compared to controls. Additionally, the authors did not find differences on non-p-
tau levels between patients in the MCI and the dementia stages of AD, in agreement with the 
presence of increased t-tau concentrations in MCI [43, 46, 125].
One of the major handicaps in the use of t-tau and p-tau concentrations in the differential 
diagnosis of neurodegenerative dementias is the partial overlap on both biomarkers among 
several conditions [17, 22, 83]. Thus, it could be hypothesized that the comparative study 
of non-p-tau in diseases with brain injury (elevated t-tau), but differential tau pathology 
could improve the discrimination achieved by both t-tau and p-tau. In this regard, a recent 
study investigated if non-p-tau quantification could improve the current diagnostic perfor-
mance of the AD-associated CSF biomarker panel (amyloid beta-42, t-tau and p-tau-181) 
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in differential diagnosis of four neurodegenerative dementias (AD, FTLD, DLB, CJD) 
[107]. While the authors concluded that non-p-tau quantification had no added diagnostic 
value as a CSF biomarker for the differential diagnosis of neurodegenerative dementia, it 
improved the discrimination of sCJD cases. Unfortunately, as t-tau levels were above the 
quantification limit in 17 out of 19 CJD cases analyzed in this study, no significant conclu-
sions could be drawn on the differential diagnostic accuracy of both tests.
In summary, preliminary observations indicate that the non-p-tau assay may be an interesting 
additional tool for the study of the dissociation between neuronal damage and tau pathology 
in the brain and biological fluids of neurodegenerative disorders.
3.5. Tau truncated forms
A growing body of literature is pointing to tau fragments, produced by cleavage events, as 
major players in the onset and the progression of the pathology [126–129]. In AD brains, after 
an initial misfolding at early stages of the disease which involves the physical contact of the 
N-terminal region with the microtubule binding repeats, tau is cleaved first at residue D421 
followed by cleavage at residue E391, while N-terminal cleavage appears in later stages of 
the disease [126, 130]. The differential enzymatic cleavages during the pathological process 
is mostly dependent on Caspases activation, which lead to the generation of several tau frag-
ments, each displaying its own profile of neurotoxicity [131]. Additionally, Calpain proteases 
have been shown to produce a triplet of tau fragments spanning from 35 kDa to 15 kDa. 
Similarly to full length tau [132, 133], several reports have shown that tau fragments can be 
secreted and uptaken from cells and brain slices and mediate toxicity [134–136].
These and other findings led researchers to investigate the presence of tau fragments in CSF 
and other biological fluids as potential biomarkers for the differential diagnosis of tauopathies 
and associated diseases. In CSF, at least 10 fragments were characterized in AD by mass spec-
trometry [137]. The presence of the 20 kDa caspase-6 cleavage product of tau in the CSF of AD 
has been reported to be associated with brain pathology and was found to be increased with 
the severity of the disease and the overall measure of global cognition [138]. Other reports 
found a 26–28 kDa fragment in both AD and strokes patients [139]. Tau bands ranging from 
20 to 40 kDa were found in AD and control CSF [140, 141], which corresponded to N-terminal 
and mid-domain fragments, while no C-terminal fragments were found. Therefore, bio-
marker-based diagnosis would strongly depend on the subset of tau species analyzed.
Tau fragments have been proposed as biomarkers not only for the discrimination of AD from 
controls, but also for the differential diagnosis within related neurodegenerative diseases. For 
instance, a divergent pattern of expression of different N-terminal tau fragments was found 
between AD and PSP, even though such kind of studies are limited by the frequently overlap-
ping clinical diagnosis [142]. Nonetheless, the ratio between a 33 kDa and a 55 kDa fragment 
in CSF was proposed as a more specific and reliable biomarker for the diagnosis of PSP [63]. 
Moreover, in CSF derived from TBI patients, a 30–50 kDa tau fragment was found to correlate 
with the extent of axonal damage [143]. Lastly, in CSF derived from either lumbar or cervical 
puncture from amyotrophic lateral sclerosis (ALS) patients the neurotoxic 17 kDa fragment 
produced by calpain cleavage was found to be elevated compared to controls [144].
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While no C-terminal tau fragment was detected in CSF, a combination of ELISA and mass 
spectrometry analysis [145] revealed the presence of a C-terminal tau fragments in serum 
derived from AD patients. The levels of this fragment inversely correlated with the Mattis 
Dementia Rating Scale, suggesting that the increase of the fragment in the serum might paral-
lel the cognitive decline.
3.6. Tau-seeding-based assays
The development and implementation of seeding-based methodologies for disease diag-
nostic purposes is an emerging topic with demonstrated clinical applicability in the field of 
prion diseases due to the real-time quaking-induced conversion assay (RT-QuIC). This assay 
exploits the self-propagating replication capacity of the abnormally folded and pathogenic 
PrP (seed), which induce the misfolding of naive PrP molecules (template) into a similar 
pathogenic structure. This reaction can be amplified to detectable levels and quantified in 
real-time. Importantly, the use of CSF from prion disease cases as a seeding material in the 
RT-QuIC assay allows the discrimination of CJD from non-CJD cases with high diagnostic 
accuracy and almost full specificity [146, 147].
Although the precise mechanism of neurofibrillary tangle formation in the brain tissue is 
not fully understood, the observation of tau spreading implicates the presence of a prion-
like pathogenesis, where abnormal tau forms may induce the misfolding of non-pathological 
forms in a regional-dependent manner. Therefore, the principles of the RT-QuIC assay could 
be applied to the amplification of tau pathological forms in biological tissues. Although, suc-
cessful cell- and tissue-based tau seeding assays have been recently developed the presence of 
tau seeding activity in the CSF of a tau-related pathology has been only reported once. Saijo 
et al. developed a tau RT-QuIC based on the use of a 3-repeat tau fragment as a substrate, a 
tau isoform that preferentially accumulates in Pick bodies. The authors detected positive tau 
RT-QUIC signal in the CSF from Pick disease (PiD) cases, suggesting that this assay may be 
helpful in discriminating PiD and non-PiD cases [148].
4. Tau in blood-based biofluids
Although lumbar puncture is a routine technique in the diagnosis of neurological syndromes, 
it entails important side effects for the patient being headache and cranial nerves dysfunction 
the most frequent ones [149, 150]. Therefore, many efforts are focused to identify biomarkers 
in other body fluids. Among them, blood analysis has arisen as a promising and cost-effective 
tool to identify biomarker molecules out of the CSF. Besides avoiding side-effects associated 
to lumbar puncture, blood extraction is suitable to be practiced in ambulatory centers or in 
home visits for first disease screening. However, the blood-CSF barrier imposes a decrease in 
the concentration of brain-specific molecules in the blood compared to that found in the CSF, 
which creates the need to develop ultra-sensitive quantification methods [151]. Several works 
have investigated the use of amyloid-beta peptides levels in plasma as a biomarker candidate 
for AD, but little research is done for other proteins [152, 153].
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Owing to the lack of high-sensitive techniques and the low amount of tau in blood com-
pared to CSF, the initial measurement of tau in human plasma was technically complicated 
impeding the detection of this molecule in 80% of samples [154]. However, novel quantifica-
tion methods were later developed to overcome this limitation. They include immunoassays 
based on carboxylated microsphere beads [155], digital array technology [156], immunomag-
netic reduction assay [157, 158] and ultra-sensitive commercial ELISA kits [159]. This way, in 
the recent years, plasma tau has arisen as a promising biomarker in neurodegenerative con-
ditions. Importantly, it does not show significant correlation with demographic parameters 
such as age, sex or educational level [160].
Although a study showed reduced plasma t-tau levels in AD patients compared to normal 
cognitive individuals [159], the current consensus data point toward the opposite direction. 
Indeed, in the blood-based diagnostics of AD, t-tau is the only significant biomarker in the dis-
crimination of the disease, displaying an AD/control mean ratio between 1.5 and 4.5 [42, 161]. 
The use of an assay based on antibodies coupled to magnetic nanoparticles rendered very high 
values (>90%) of specificity and sensitivity when comparing healthy controls versus AD+MCI 
cases [157]. This method was subsequently validated in a study enrolling two independent 
cohorts, where those high levels of specificity and sensitivity were almost reached (>89%) in 
the combination of cohorts when comparing healthy with AD cases [162]. With these data, 
the authors concluded that the best performance of plasma t-tau in the AD diagnostics was 
in combination with plasma Amyloid beta-42 levels, in a similar manner than combination 
biomarkers increase the diagnostic accuracy of single measurement markers in the CSF [18].
In the differential diagnostic context, plasma t-tau also appeared elevated in AD compared 
to MCI. However, the overlap between groups hinders the clinical utility of plasma t-tau 
as a routine biomarker [163]. Plasma t-tau was not found increased in MCI cases that later 
developed AD compared to controls, neither in cases with pre-MCI stage of subjective cogni-
tive decline (SCD) [164]. These findings suggest that plasma t-tau is a late marker of neuro-
nal damage and cannot be used as a prognostic tool of the likelihood to develop AD-related 
dementia sensitivity of the methodologies is improved.
Plasma t-tau does not seem to be a good reporter of the tau pathology in AD brain, as no 
strong correlation between plasma and CSF t-tau could be soundly demonstrated so far 
in AD [163]. However, plasma and CSF t-tau appeared correlated in a very recent study 
performed in a cohort with various neurological syndromes [161]. On the other side, mild 
association of high plasma t-tau with AD-specific pathology cannot be discarded. Within 
the MCI group, those cases positive for amyloid beta-42 had elevated t-tau compared with 
those amyloid beta-42 negatives [163]. In addition, high plasma t-tau levels in AD patients 
are associated to rapid disease progression in late clinical stages, including cognitive impair-
ment and brain dysfunction [163]. The detailed relationship between plasma t-tau and the 
pathological state of the brain during the course of the disease is not yet clear. The t-tau 
concentration in plasma has been associated to abnormal cortical thickness and memory 
performance in a cohort of MCI patients [165]. However, in another cohort of MCI and AD 
cases, plasma t-tau appeared unrelated to cortical thickness in AD-specific regions [166]. In 
the same study though, the authors did report a significant association of high plasma t-tau 
levels and reduced gray matter density.
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Specific measurement of p-tau in plasma still represents a technical challenge. One of the 
first attempts to measure p-tau-231 in human plasma was based on a complex immuno-
assay using multi-arrayed fiber optics coupled to rolling circle amplification (a-EIMAF) 
[167]. Although the authors only measured 5 sCJD plasma samples and 5 controls, t-tau 
was increased in all the disease cases. By contrast, no differences between p-tau-231 levels 
were detected. Interestingly, a similar pattern of t-tau and p-tau-231 was found in the brain 
tissue. It should be noted that the authors used arbitrary units for p-tau-231 quantification 
due to technical impediment [167]. Very recently, fine quantification of plasma p-tau-181 
has been possible using a novel immunoassay based on digital array technology that has 
been modified to detect this phosphorylated form. In an exploratory case–control study 
that included 3 small cohorts (<50 cases per cohort), AD, Down syndrome (DS), neurologi-
cal controls and healthy controls were analyzed [168]. In general, p-tau-181 was specifically 
increased in AD and DS patients compared to controls. Correlation between age and p-tau-
181 was found in the DS group, supporting the link between this protein and the presence 
of amyloid pathology. A striking correlation was also found between p-tau-181 levels in 
plasma and in CSF, in contrast to the weak or no correlation between CSF and plasma t-tau 
[160]. Therefore, it is possible that phosphorylated tau, in contrast to t-tau in blood, is only 
originated in the brain.
Besides plasma, the levels of t-tau and p-tau-181 have been recently evaluated in the serum 
of AD cases by real time Surface Plasmon Resonance. Both concentrations were increased in 
AD compared to controls, with a better performance of tau than p-tau-181. Tau was also sig-
nificantly elevated in AD compared to MCI. Tau and p-tau-181 in serum appeared strongly 
correlated, which could mean un-specificity in the CSF-blood filtration of tau species [169]. 
Similar to plasma, serum tau levels also presented a negative correlation with scores of cogni-
tive assessment (HMSE and MoCA).
Blood tau levels have also been investigated in rapid progressive dementias. One of the pio-
neering works reported an increase of t-tau levels in serum in CJD patients compared of those 
is serum of AD and other non-CJD rapid progressive dementias. In spite of the small number 
of cases analyzed (<15 per group), it provided a valid proof-of-concept toward measuring 
t-tau in blood to differentially diagnose CJD [170]. A very recent study has validated these 
data using a larger and autopsy confirmed cohort. The levels of plasma tau in sporadic CJD 
appeared more than 2-fold elevated compared to neurological controls and to AD. Genetic 
CJD cases also presented increased plasma tau compared to AD. Comparison among differ-
ent subtypes of sCJD also revealed differences in plasma tau, which was higher in MM/MV1 
and MM1 + 2 subtypes. On the opposite, the subtype MV2 (kuru plaque) presented the lowest 
levels of plasma tau among the disease group [161]. These results indicate that plasma t-tau 
may be also reflecting the subtype-specific hallmarks of sCJD pathology.
5. Tau in the evaluation of disease-modifying therapies
Several strategies have been considered in order to prevent tau deposition. Compounds 
inhibiting tau aggregation [171], stimulating immune system against misfolded and 
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phosphorylated tau, as well as inhibiting of kinases responsible for tau hyper-phosphor-
ylation, especially glycogen synthase kinase-3, have been proposed [172–174]. Therefore, 
tau and p-tau quantification in biological fluids is emerging as a potential tool in the 
evaluation of disease-modifying therapies. On one hand, alterations in p-tau levels would 
be informative of the phosphorylation and aggregation state of tau in the brain tissue. On 
the other hand, therapeutic approaches preventing neuronal damage would also alter the 
levels of t-tau protein in the CSF.
Interestingly, decreased CSF p-tau levels have been reported in patients treated with bap-
ineuzumab, an antibody capable of binding to soluble and fibrillary forms of amyloid 
beta despite clinical trials do not lead to clinical benefit for intravenous bapineuzumab 
treatment [175].
However, as this research field is in its early phases, longitudinal studies are required to 
definitely demonstrate the relationship between temporal alterations in tau levels and clinical 
outcome. Additionally, as the effect of disease-modifying therapies on CSF biomarkers may 
be influenced by the mechanism of action of the therapeutic compound, alternative biomark-
ers should be used in order to assess the complete panel of hallmarks associated to the neu-
rodegenerative process.
6. Conclusion
CSF t-tau and p-tau concentrations display good sensitivity and specificity in the discrimina-
tion of AD patients from non-demented control cases and a high diagnostic accuracy in the 
discrimination of sCJD cases. Both biomarkers become useful in the identification of patients 
at risk of progression to AD. The partial overlap between t-tau and p-tau levels among several 
neurodegenerative dementias indicates that more specific biomarkers are required in order to 
improve the accuracy in the differential diagnostic context. Alternative tau-based approaches 
have been recently developed and form the basis of the second-generation tau assays. On one 
side, the use of composite biomarkers, the development of non-p-tau assays and tau seed-
ing methodologies, and the detection of tau truncated forms and alternative phosphorylation 
sites are promising alternatives that need further research to maximize their potential as diag-
nostic and prognostic tools. On the other side, the quantification of tau in blood-based fluids 
is gaining experimental momentum due to the advantages of using blood instead of CSF and 
to the implementation of high-sensitivity tests that can detect scarce tau amounts in plasma 
and serum. Several contradictory findings in the field might be related to the use of differen-
tial methodologies, which in some of the cases are not yet fully implemented and validated in 
large and independent cohorts.
Finally, the clinical diagnostic utility of tau measurements is complemented by the role of this 
protein as a reporter of the degree of neuro-axonal damage in the brain and the pathological 
hyper-phosphorylation tau state, which is specifically present in tauopathies. Since we are in 
the dawning of second-generation tau assays, future studies are necessary to validate them in 
larger and independent cohorts of patients in order to prove their clinical utility while they 
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might provide important clues toward understanding the molecular events taking place in 
neurodegenerative processes.
A summary of the findings on tau-related biomarkers in the CSF and blood of neurodegenera-
tive dementias is shown in Table 1.
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